ArticleFood science & nutrition2025
Resveratrol Downregulated PRDX4 Expression to Inhibit the Progression of Renal Cell Carcinoma via Wnt/β-Catenin Pathway.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Engineering alginate hydrogels loaded with resveratrol as a dual platform for cancer therapy and wound regeneration.Discover nano · 2026Review
- Peroxiredoxin 4 suppresses ferroptosis in esophageal squamous cell carcinoma by activating the phosphoinositide 3-kinase signaling pathway.Biomedical reports · 2026Article
- [Erianin inhibits proliferation and migration of breast cancer cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Emerging role of lncRNA TP53TG1 as a tumor regulator and biomarker in human malignancies.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is a common urological cancer. Resveratrol, a natural plant polyphenol, has demonstrated antitumor efficacy in various human cancers. Despite its recognized potential, the specific impact of resveratrol on RCC remains unclear. This study aimed to ascertain the potential of resveratrol in suppressing RCC progression and to elucidate the intricate molecular mechanisms governing its effects. The CCK8 assay outcomes indicate that resveratrol inhibits RCC cell viability in a dose-dependent manner. Transwell and wound healing assays confirmed the inhibitory effects of resveratrol on RCC cell invasion and migration. Flow cytometry further demonstrated that resveratrol induced apoptosis in RCC cells. Additionally, in vivo experiments have established the ability of resveratrol to impede RCC tumor growth. Mechanistically, resveratrol exhibits its inhibitory influence on RCC cells by downregulating PRDX4 expression, consequently weakening the Wnt/β-catenin pathway. These findings gain support from experiments utilizing a Wnt/β-catenin pathway activator. In summary, our results suggest that resveratrol impedes the progression of RCC by inhibiting the Wnt/β-catenin signaling pathway via the downregulation of PRDX4.PRDX4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.